Mikart Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Mikart's estimated annual revenue is currently $35.2M per year.(i)
  • Mikart's estimated revenue per employee is $218,478

Employee Data

  • Mikart has 161 Employees.(i)
  • Mikart grew their employee count by 11% last year.

Mikart's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
CEOReveal Email/Phone
3
VP, Product DevelopmentReveal Email/Phone
4
VP MarketingReveal Email/Phone
5
ControllerReveal Email/Phone
6
VP, Quality and RegulatoryReveal Email/Phone
7
Director Engineering and FacilitiesReveal Email/Phone
8
Human Resources DirectorReveal Email/Phone
9
Director, Supply ChainReveal Email/Phone
10
Director Formulation DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.5M1228%N/AN/A
#2
$10.7M43-2%N/AN/A
#3
$9.2M462%N/AN/A
#4
$24.1M12021%N/AN/A
#5
$7.2M28-7%N/AN/A
#6
$27.7M74-35%N/AN/A
#7
$39.8M19837%N/AN/A
#8
$0.5M11120%$50MN/A
#9
$13.7M51-9%N/AN/A
#10
$10.3M41-2%N/AN/A
Add Company

What Is Mikart?

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. The company also provides specialty packaging and research support services. A recognized CDMO leader since 1975, Mikart has a wealth of expertise in pharmaceutical development, contract manufacturing and packaging services. Our manufacturing experience includes a broad range of drug compounds, including controlled drug substances.

keywords:N/A

N/A

Total Funding

161

Number of Employees

$35.2M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mikart News

2022-04-19 - Dicyclomine Market Size, Scope And Forecast | Axcan ...

... Lannett, Mutual Pharmaceutical, Mylan, Pioneer Pharmaceuticals, Watson Laboratories, Hikma Pharmaceuticals, Alpharma and Mikart.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$38.1M161-15%N/A
#2
$27.8M161-4%N/A
#3
$59M161-5%N/A
#4
$7.5M16114%N/A
#5
$71.1M1626%N/A